Table 1 Patient characteristics
Characteristics | Value (N = 19 patients) |
|---|---|
Female, n (%) | 6 (32) |
Age, mean (SD) | 65.3 (9.7) |
Body mass index (kg/m2), median (25–75th percentile) | 29.7 (22.5–32.7) |
SAPS II at ICU admission, mean (SD) | 57.5 (24) |
Main diagnosis | |
Pneumonia, n (%) | 4 (21) |
Sepsis, n (%) | 1 (5) |
COPD/asthma exacerbation, n (%) | 1 (5) |
Cardiac failure, n (%) | 3 (16) |
Drug overdose/acute mental status change, n (%) | 5 (26) |
Intra-abdominal sepsis with surgery, n (%) | 5 (26) |
Co-morbidity | |
Chronic pulmonary disease, n (%) | 6 (32) |
Obesity, n (%) | 9 (47) |
Chronic cardiac insufficiency, n (%) | 5 (26) |
Cancer, n (%) | 1 (5) |
Chronic kidney disease, n (%) | 3 (16) |
Diabetes mellitus, n (%) | 7 (37) |
Between admission and inclusion | |
Septic shock, n (%) | 6 (31) |
ARDS, n (%) | 5 (26) |
Renal failure, n (%) | 8 (42) |
Use of cathecolamines, n (%) | 13 (68) |
Use of neuromuscular blockers, n (%) | 10 (53) |
No. of days of neuromuscular blockers, median (25–75th percentile) | 1 (0–2) |
Ventilator use (days), median (25–75th percentile) | 4 (2–7) |
Ventilator parameters and sedation use during protocol | |
Pressure support (cmH2O), mean (SD) | 15 (3) |
Positive end-expiratory pressure (cmH2O), mean (SD) | 7 (1) |
Fraction of inspired oxygen (%), mean (SD) | 35 (13) |
Midazolam mg/h, mean (SD) | 5 (4) |